Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
UBS
US Department of Justice
Daiichi Sankyo
Express Scripts
Johnson and Johnson
Julphar
Mallinckrodt
Colorcon

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BENICAR

« Back to Dashboard

Clinical Trials for Benicar

Trial ID Title Status Sponsor Phase Summary
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Daiichi Sankyo Inc. N/A The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Center for Research Resources (NCRR) N/A The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00122447 Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance Completed Emory University N/A The purpose of this study is to determine whether cardiovascular disease (CVD) risk markers, β-cell function, and insulin sensitivity can be improved by targeting mechanisms of both diabetes and CVD - using an antioxidant, an angiotensin II receptor blocker (ARB), or an anti-inflammatory agent - in patients with impaired glucose tolerance (IGT) in a randomized, controlled trial.
NCT00185068 An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension Completed Daiichi Sankyo Inc. Phase 4 Effect of increasing doses of olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide on blood pressure in patients with hypertension
NCT00362115 Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension Completed Takeda Phase 2 The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Benicar

Condition Name

Condition Name for Benicar
Intervention Trials
Healthy 4
Hypertension 2
Healthy Subjects 2
Coronary Atherosclerosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Benicar
Intervention Trials
Hypertension 3
Cardiovascular Diseases 1
Myocardial Ischemia 1
Coronary Artery Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Benicar

Trials by Country

Trials by Country for Benicar
Location Trials
United States 63
Mexico 5
Chile 4
Peru 1
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Benicar
Location Trials
North Dakota 4
California 3
Wisconsin 3
Oklahoma 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Benicar

Clinical Trial Phase

Clinical Trial Phase for Benicar
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Benicar
Clinical Trial Phase Trials
Completed 10
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Benicar

Sponsor Name

Sponsor Name for Benicar
Sponsor Trials
Mylan Pharmaceuticals 4
Torrent Pharmaceuticals Limited 2
Daiichi Sankyo Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Benicar
Sponsor Trials
Industry 10
Other 2
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
Express Scripts
Baxter
Farmers Insurance
Teva
Julphar
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.